Isolation of Leukocytes from Human Breast Milk for Use in an Antibody-dependent Cellular Phagocytosis Assay of HIV Targets

Summary

Breast milk transmits human immunodeficiency virus (HIV), though only ~15% of infants breastfed by HIV-infected mothers become infected. Breastfed infants ingest ~10⁵−10⁸ maternal leukocytes daily, though these cells are understudied. Here we describe the isolation of breast milk leukocytes and an analysis of their phagocytic capacity.

Abstract

Even in the absence of antiretroviral drugs, only ~15% of infants breastfed by HIV-infected mothers become infected, suggesting a strong protective effect of breast milk (BM). Unless access to clean water and appropriate infant formula is reliable, the WHO does not recommend cessation of breastfeeding for HIV-infected mothers. Numerous factors likely work in tandem to reduce BM transmission. Breastfed infants ingest ~10⁵−10⁸ maternal leukocytes daily, though what remains largely unclear is the contribution of these cells to the antiviral qualities of BM. Presently we aimed to isolate cells from human BM in order to measure antibody-dependent cellular phagocytosis (ADCP), one of the most essential and pervasive innate immune responses, by BM phagocytes against HIV targets. Cells were isolated from 5 human BM samples obtained at various stages of lactation. Isolation was carried out via gentle centrifugation followed by careful removal of milk fat and repeated washing of the cell pellet. Fluorescent beads coated with HIV envelope (Env) epitope were used as targets for analysis of ADCP. Cells were stained with the CD45 surface marker to identify leukocytes. It was found that ADCP activity was significant above control experiments and reproducibly measurable using an HIV-specific antibody 830A.

Introduction

Human breast milk (BM) is comprised of maternal cells that are >90% viable¹. Cell composition is impacted strongly by stage of lactation, health status of mother and infant, and individual variation, which remains poorly understood^1,2,3,4. Given that BM contains ~10³−10⁵ leukocytes/mL, it can be estimated that breastfed infants ingest ~10⁵−10⁸ maternal leukocytes daily⁵. Various in vivo studies have demonstrated that maternal leukocytes provide critical immunity to the infant and are functional well beyond these sites of initial ingestion^{5,6,7,8,9,10,11}. All maternally-derived cells ingested by the infant have the potential to perform immune functions alongside or to compensate for the infant's own leukocytes¹².

Mother-to-child transmission (MTCT) of human immunodeficiency virus (HIV) remains a crisis in resource-limited countries. As diarrheal and respiratory diseases are responsible for substantial rates of mortality among infants in resource-limited countries, and these illnesses are significantly reduced by exclusive breastfeeding, the benefits to HIV-infected mothers of breastfeeding far outweigh the risks^13,14,15. Unless access to clean water and appropriate infant formula is reliable, the WHO does not recommend cessation of breastfeeding for HIV-infected mothers¹⁶. Approximately 100,000 MTCTs via BM occur annually; yet, only ~15% of infants breastfed by their HIV-infected mothers become infected, suggesting a strong protective effect of BM^{17,18,19,20,21}. Numerous factors likely work in tandem to prevent transmission. Importantly, HIV-specific antibodies (Abs) in BM have been correlated with reduced MTCT and/or reduced infant death from HIV infection^22,23. What remains largely unclear is the contribution of the cellular fraction of BM to its antiviral qualities.

Many Abs facilitate a variety of anti-viral activities mediated by the 'constant' region of the immunoglobulin molecule, the crystallizable fragment (Fc), via interaction with Fc receptors (FcRs) found on virtually all innate immune cells, virtually all of which are found in human BM²⁴. Antibody-dependent cellular phagocytosis (ADCP) has been demonstrated as necessary for the clearance of viral infections and has been understudied in the case of prevention of MTCT of HIV^{25,26,27,28,29}. Given the paucity of knowledge about the potential contribution of ADCP activity by BM phagocytes to prevention of MTCT of HIV, we aimed to develop a rigorous method to isolate cells from human BM in order to undertake a study of ADCP mediated by cells from BM obtained at various stages of lactation.

Protocol

Each participant in this study was recruited and interviewed in accord with the ethical and institutional review board (IRB) approval with the guidance and authorization of Mount Sinai’s Program for the Protection of Human Subjects (PPHS) using an IRB-approved protocol for obtaining breast milk samples.

1. Target Microsphere preparation

1. Select a relevant target antigen.
   NOTE: In this example, the recombinant protein V1V2-2F5K was used, which was designed to mimic the trimeric apex of native HIV envelope³⁰.
2. Perform biotinylation using a commercial kit (Table of Materials) according to the manufacturer’s protocol.
   1. Calculate mmol of the biotin reagent to add to the reaction for a 5-fold molar excess using the formula: mmol biotin = mL protein x (mg protein/mL protein) x (mmol biotin/mg protein) x (5 mmol biotin/mmol protein)^30,31. Then calculate µL of the biotin reagent to add using the formula: µL biotin = mmol biotin x (1,000,000 µL/L) x (L/10 mmol).
   2. Equilibrate biotin to room temperature before opening. Dissolve protein in 0.5−2.0 mL of phosphate-buffered saline (PBS) according to the calculation made above.
   3. Prepare a 10 mM solution of biotin reagent in dimethylsulfoxide (DMSO) and add the appropriate volume of 10 mM biotin reagent to the protein solution, and incubate reaction on ice for 2 h or at room temperature for 30 min.
3. Remove excess biotin using protein concentrators (polyethersulfone [PES] membranes, 3 kDa molecular weight cut-off [MWCO], 0.5 mL; Table of Materials) according to the manufacturer’s instructions.
   1. Deposit sample into the upper chamber of spin column and add PBS up to 400 µL. Cap, then insert this sample chamber into a collection tube. Centrifuge at 12,000 x g at room temperature for 30 min.
   2. Discard flow-through and add PBS to 400 µL. Repeat centrifugation. Discard flow-through and add PBS to 100 µL. Measure protein concentration by a spectrophotometer.
      NOTE: Protein can be aliquoted and frozen at -80 °C until used.

2. Antibody-Dependent Cellular Phagocytosis (ADCP) Assay Plate Preparation

1. Conjugate biotinylated protein to 1 µm microspheres (‘beads’; Table of Materials) according to the manufacturer’s instructions.
   1. Per plate of conjugated beads, incubate 6 µg of protein with 12 µL of stock beads in 200 µL of 0.1% bovine serum albumin (BSA)-PBS at room temperature for 1 h, vortexing gently every 20 min.
   2. Centrifuge at 13,000 x g for 5 min. Discard supernatant, vortex gently and resuspend in 1200 µL of 0.1% BSA-PBS. Repeat spin and wash step 2x. Resuspend in 1200 µL of 0.1% BSA-PBS.
2. Aliquot 10 µL of bead solution per well in a round bottom 96-well plate. Prepare dilutions of antibody or immune sera of interest in 12 µL of 2% HSA HBSS, typically starting at 50 µg/mL of antibody or a 1/100 serum dilution.
   NOTE: In the sample data, monoclonal antibody (mAb) 830A was used.
3. Add 10 µL of titrated antibody/sera to the bead plate and incubate for 2 h at 37 °C. Add 200 µL of 2% HSA HBSS to each well and centrifuge plate at 2,000 x g for 10 min.
4. Carefully remove supernatant by a rapid overturning and decanting of liquid from the plate wells into a sink to avoid disturbing the invisible bead pellet.

3. Breast milk cell isolation

1. Obtain human breast milk from healthy lactating women, expressed using double electronic or manual pumps. Isolate cells within ~4 h of expression, keeping milk at room temperature.
2. Using 50 mL tubes, centrifuge 50 mL milk at 800 x g for 15 min. Carefully pour off the skim milk and fat while leaving the cell pellet undisturbed. Wipe the inside of the tube with a lint-free wipe to remove all fat from the tube wall.
3. Add 10 mL of 2% human serum albumen in Hank’s balanced salt solution (2% HSA HBSS [without Ca²⁺ or Mg⁺]). Resuspend the pellet by gentle pipetting to avoid cell activation and apoptosis. Transfer to a 15 mL tube and centrifuge at 450 x g for 10 min.
4. Pour off supernatant and repeat step 1.3. Then, gently resuspend cells in 1−2 mL of 2% HSA HBSS depending on expected cell number, and count cells by a hemocytometer or an automated cell counter, noting also the cell viability.

4. ADCP assay

NOTE: Methods described here are adapted from Ackerman et al.³².

1. Add 50,000 freshly isolated BM cells to each ADCP assay plate well in 200 µL of 2% HSA-HBSS. Incubate for 2 h at 37 °C.
   1. For control experiments, pre-incubate cells at 37 °C with 10 µg/mL actin inhibitor (cytochalasin-D), 50 µg/mL FcR blocking agent (FcBlock), or a combination of both prior to their addition to the plates.
2. Centrifuge plate at 930 x g for 10 min. Add 200 µL of 2% HSA HBSS and repeat centrifugation. Carefully remove supernatant as in step 2.7 and repeat wash.
3. Carefully remove supernatant and stain cells for viability using 0.5 µg/mL (final concentration) fixable viability stain 450 per well in 50 µL of 2% HSA HBSS. Incubate 20 min at room temperature in the dark. Centrifuge plate at 930 x g for 10 min and remove supernatant as in step 2.7. Add 200 µL of 2% HSA HBSS and centrifuge plate again followed by removal of supernatant as in step 2.7.
4. After viability staining, stain cells for leukocyte markers of interest, minimally including a CD45-specific stain such as PE-mouse anti-human CD45 (clone HI30) at an optimized concentration (1 µg/µL in 50 µL of 1% BSA HBSS in the example data).
   NOTE: Any lineage-specific markers of interest can be included.
5. Incubate 20 min at room temperature in the dark. Centrifuge plate at 930 x g for 10 min and remove supernatant as in step 2.7. Add 200 µL of 1% BSA HBSS and repeat centrifugation. Remove supernatant. Fix cells in 200 µL of 0.5% formaldehyde in the dark at room temperature for 30 min or overnight at 4 °C. Refrigerate in the dark until analysis.

5.  Analysis by flow cytometry

1. Perform initial gating to eliminate doublets on a forward scatter (FSC) vs. side scatter (SSC) plot and debris (material smaller than FSC = 5000) (see Figure 1). Use an SSC vs. viability stain (V450 in this case) plot to eliminate dead cells (those that are positive for viability stain).
2. Use an SSC vs. CD45 plot to differentiate the major leukocyte classes (granulocytes, monocytes, lymphocytes) as extensively described^33,34.
   NOTE: This classification is only suggestive and lineage-specific markers are needed to confirm cell type.
3. For all CD45+ cells, or for each leukocyte subset of interest, measure ADCP activity by gating with a marker on the bead-positive cells in a histogram of the fluorescein isothiocyanate (FITC) channel, where the fluorescent beads are detected.
   NOTE: The negative control wells in which beads were not added will indicate where the bead-positive cells are apparent in the histogram and therefore where to place the gating marker.
4. Calculate ADCP scores as (median fluorescence intensity [MFI] of bead-positive cells) x (% of total CD45 + cells in the positive population). Use graphics software to plot scores at each Ab/serum concentration and to perform an area-under-the-curve (AUC) analysis.
   NOTE: ADCP is considered positive if the AUC is greater than 3x standard deviation of the ADCP score AUC of a non-specific negative control mAb (in this case, 3865).

Results

Milk can be kept at room temperature or cooler (though not frozen); however, given that we have observed reduced viability when milk has been kept very cold (data not shown), and that it is simpler to collect, store briefly, and transport at ambient temperatures, it is recommended that samples are not refrigerated in order to reduce sample-to-sample variability. In milk obtained 7−183 days post-partum, cell concentration determined by automated cell counter ranged from 16,083−222,857 cell...

Discussion

The flow cytometry-based technique for measuring ADCP activity described herein was first described in 2011³⁰ and has since been proven robust and cited in more than 80 studies. The protocol described here adapts this technique for use with primary BM cells for the first time. Previous studies of Fc-mediated functionality by BM cells have been largely limited to measurement of oxidative bursts or histology-based phagocytosis assays using cells isolated from colostrum (0−4 days after birth). ...

Materials

List of materials used in this article

Name	Company	Catalog Number	Comments
1 µm FluoSpheres NeutrAvidin-Labeled Microspheres	Thermo Fisher	F8776
BD Pharmingen PE Mouse Anti-Human CD45	BD	560975
Bovine serum Albumin	MP Biomedicals	8810025
Corning V-bottom polystyrene 96-well plate	Corning	3894
Cytochalasin D	Sigma	22144-77-0
EZ-Link NHS-LC-LC-Biotin kit	Thermo Fisher	21338
Falcon 15 mL Conical Centrifuge Tubes	Corning	352196
Falcon 50 mL Conical Centrifuge Tubes	Corning	352070
Fixable Viability Stain 450	BD	562247
Formaldehyde solution	Sigma	252549
HBSS without Calcium, Magnesium or Phenol Red	Life Technologies	14175-095
Human BD Fc Block	BD	564219
Human Serum Albumin	MP Biomedicals	2191349
Kimtech Science Kimwipes Delicate Task Wipers	Kimberly-Clark Professional	34120
PBS 1x pH 7.4	Thermo Fisher	10010023
Polystyrene 10 mL Serological Pipettes	Corning	4488
Protein Concentrators PES, 3K MWCO, 0.5 mL	Pierce	88512